Developing and Testing a novel, low-cost, effective HOOKworm VACcine to Control Human Hookworm Infection in endemic countries

Fact Sheet

Project information

HOOKVAC

Grant agreement ID: 602843
Status
Closed project

Funded under:
FP7-HEALTH

Overall budget:
€ 7 669 416,40

EU contribution
€ 5 999 983

Coordinated by:
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands

Start date
1 October 2013
End date
31 March 2019

Objective

Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease, and among the top 3 in terms of lost Disability-Adjusted Life Years. HOOKVAC will be developing the first and only vaccine for human hookworm infection. A bivalent, low-cost vaccine candidate will be clinically tested for the first time in an African disease endemic population. This will be done in Gabon in a very typical setting within the Central African rainforest belt, where the incidence of hookworm infections is 30%. Inspired by preparatory research, HOOKVAC believes that it can develop the vaccine with at least 80% efficacy against moderate and heavy hookworm infections that lasts at five years after immunization. Cost effectiveness modelling has shown that such a vaccine will significantly improve the efficacy of the current mass drug administration programs. HOOKVAC will play a crucial role in advancing toward large scale efficacy studies in African endemic areas. Via a program of 48 months with 6 work packages, HOOKVAC will address 4 main objectives: (1) establish safety and immunogenicity of the vaccine candidate in an endemic population (2) improve the manufacturing process (3) provide clinical proof of concept (4) improve accessibility of the vaccine in endemic areas. The
involvement of European SMEs in the project is a critical component to advancing a successful vaccine, and an integral part of adding private sector know-how and scientific expertise to the project. This will inspire other European SMEs to become more involved in public/private vaccine product development for neglected infectious diseases. By doing so, HOOKVAC will fuel a follow-up programme for further development of the vaccine towards into a licensed product.

Field of Science

/medical and health sciences/health sciences/infectious disease

Programme(s)

FP7-HEALTH - Specific Programme "Cooperation": Health

Topic(s)

HEALTH.2013.2.3.0-1 - Innovation in vaccines

Call for proposal

FP7-HEALTH-2013-INNOVATION-1

See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Address

Meibergdreef 15
1105az Amsterdam
Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 773 844

Website

Contact the organisation

Administrative Contact

Friso Janssen (Mr.)

Participants (8)
<table>
<thead>
<tr>
<th>Organization</th>
<th>Country</th>
<th>Activity Type</th>
<th>EU Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALBERT B. SABIN VACCINE INSTITUTE INC</td>
<td>United States</td>
<td>Research Organisations</td>
<td>€ 420 816</td>
</tr>
<tr>
<td>Address</td>
<td>Pennsylvania Av Nw Suite 7100 2000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administrative Contact</td>
<td>Brian Davis (Mr.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBERHARD KARLS UNIVERSITAET TUEBINGEN</td>
<td>Germany</td>
<td>Higher or Secondary Education Establishments</td>
<td>€ 47 934</td>
</tr>
<tr>
<td>Address</td>
<td>Geschwister-Scholl-Platz 72074 Tuebingen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administrative Contact</td>
<td>Ilka Westermann (Mrs.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centre de Recherches Medicales de Lambaréné</td>
<td>Gabon</td>
<td>Research Organisations</td>
<td>€ 994 800</td>
</tr>
<tr>
<td>Address</td>
<td>Na 118 LambarÉNÉ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administrative Contact</td>
<td>Ayola Akim Adegnika (Dr.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation Name</td>
<td>Country</td>
<td>EU Contribution</td>
<td>Address</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------</td>
<td>-----------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Q-BIOLOGICALS NV</td>
<td>Belgium</td>
<td>€ 1 589 690</td>
<td>Technologiepark 4 9052 Gent</td>
</tr>
<tr>
<td>Pharmidex Pharmaceutical Services Limited</td>
<td>United Kingdom</td>
<td>€ 352 291</td>
<td>Hanover Street 14 Floor 3 W1s 1rr London</td>
</tr>
<tr>
<td>ACADEMISCH ZIEKENHUIS LEIDEN</td>
<td>Netherlands</td>
<td>€ 400 230</td>
<td>Albinusdreef 2 2333 Za Leiden</td>
</tr>
<tr>
<td>Organisation Name</td>
<td>Country</td>
<td>EU Contribution</td>
<td>Activity type</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>BAYLOR COLLEGE OF MEDICINE</td>
<td>United States</td>
<td>€ 198 631</td>
<td>Higher or Secondary Education Establishments</td>
</tr>
<tr>
<td>GEORGE WASHINGTON UNIVERSITY CORPORATION</td>
<td>United States</td>
<td>€ 221 747</td>
<td>Higher or Secondary Education Establishments</td>
</tr>
</tbody>
</table>

**Share this page**

**Permalink:** [https://cordis.europa.eu/project/id/602843/en](https://cordis.europa.eu/project/id/602843/en)

© European Union, 2019